母细胞样和多形性变异型套细胞淋巴瘤患者的结局
该回顾性研究纳入2000至2015年新诊断的套细胞淋巴瘤(MCL)成人患者,其中母细胞样或多形性变异型共207例。中位随访82个月,中位无进展生存期(PFS)为38个月,中位总生存期(OS)为68个月。诱导后接受自体造血干细胞移植(auto-HCT)与PFS改善相关,但与OS无关。
要点
- 母细胞样/多形性变异型MCL患者中位PFS 38个月,中位OS 68个月。
- 诱导后auto-HCT与PFS改善相关(HR 0.52),但与OS无关(HR 0.69)。
- MIPI中危和高危评分与更差的PFS和OS相关。
核心结论
- 在母细胞样/多形性变异型MCL患者中,诱导后接受auto-HCT与PFS改善相关,但与OS无关;更高的MIPI评分和不适合auto-HCT与更差的生存相关。
研究设计与样本
- 回顾性研究,纳入2000年至2015年新诊断的套细胞淋巴瘤成人患者,共1029例,其中母细胞样或多形性变异型207例。
主要发现
- 中位随访82个月(范围0.1-174个月);中位PFS为38个月(95%CI 28-66),中位OS为68个月(95%CI 45-96)。
- 与PFS相关的因素包括:接受巩固性auto-HCT(HR 0.52,95%CI 0.31-0.80,P<.05);MIPI中危(HR 2.3,95%CI 1.2-4.3,P<.02)和高危(HR 3.8,95%CI 2.0-7.4,P<.01)评分;诱导后完全缓解(HR 0.29,95%CI 0.17-0.51)。
- 接受auto-HCT与OS无关(HR 0.69,95%CI 0.41-1.16,P=.16),但与MIPI中危(HR 5.7,95%CI 2.5-13.2,P<.01)和高危(HR 10.8,95%CI 4.7-24.9,P<.01)评分相关。
临床怎么用
- 对于符合条件的患者,诱导后接受auto-HCT与PFS改善相关,但与OS无关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma; data indicate that blastoid and pleomorphic variants have a poor prognosis. We report characteristics and outcomes of patients with blastoid/pleomorphic variants of MCL. We retrospectively studied adults with newly diagnosed MCL treated from 2000 to 2015. Primary objectives were to describe progression-free survival (PFS) and overall survival (OS). Secondary objectives included characterization of patient characteristics and treatments. Of the 1029 patients with MCL studied, a total of 207 neoplasms were blastoid or pleomorphic variants. Median follow-up period was 82 months (range, 0.1-174 months); median PFS was 38 months (95% confidence interval [CI], 28-66) and OS was 68 months (95% CI, 45-96). Factors associated with PFS were receipt of consolidative autologous hematopoietic transplantation (auto-HCT; hazard ratio [HR], 0.52; 95% CI, 0.31-0.80; P < .05), MCL International Prognostic Index (MIPI) intermediate (HR, 2.3; 95% CI, 1.2-4.3; P < .02) and high (HR, 3.8; 95% CI, 2.0-7.4; P < .01) scores, and complete response to induction (HR, 0.29 (95% CI, 0.17-0.51). Receipt of auto-HCT was not associated with OS (HR, 0.69; 95% CI, 0.41-1.16; P = .16) but was associated with MIPI intermediate (HR, 5.7; 95% CI, 2.5-13.2; P < .01) and high (HR, 10.8; 95% CI, 4.7-24.9; P < .01) scores. We report outcomes in a large cohort of patients with blastoid/pleomorphic variant MCL. For eligible patients, receipt of auto-HCT after induction was associated with improved PFS but not OS. Higher MIPI score and auto-HCT ineligibility were associated with worse survival.
引用
- Gerson JN, Handorf E, Villa D, et al. Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma. Blood Adv. 2023. PMID: 37874912. doi:10.1182/bloodadvances.2023010757
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。